Role of human cripto-1 in tumor angiogenesis

被引:67
作者
Bianco, C
Strizzi, L
Ebert, A
Chang, C
Rehman, A
Normanno, N
Guedez, L
Salloum, R
Ginsburg, E
Sun, YP
Khan, N
Hirota, M
Wallace-Jones, B
Wechselberger, C
Vonderhaar, BK
Tosato, G
Stetler-Stevenson, WG
Sanicola, M
Salomon, DS
机构
[1] NCI, Mol & Cellular Endocrinol Sect, Mammary Biol & Tumorigenesis Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA
[2] NCI, Extracellular Matrix Sect, Pathol Lab, Expt Transplantat & Immunol Branch,NIH, Bethesda, MD 20892 USA
[3] Dept Gynecol, Berlin, Germany
[4] Univ Michigan, Dept Mol & Cellular Biol, Ann Arbor, MI 48109 USA
[5] ITN, Fdn Pascale, Div Haematol Oncol, Naples, Italy
[6] ITN, Fdn Pascale, Dept Expt Oncol, Naples, Italy
[7] Upper Austrian Res GmbH Zentrum, Linz, Austria
[8] Biogen Idec Inc, Cambridge, MA USA
关键词
D O I
10.1093/jnci/dji011
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Human cripto-1 (CR-1) promotes cell transformation and increases migration and invasion of various mouse and human epithelial cell lines. We investigated whether CR-1 also stimulates angiogenesis. Methods: We used human umbilical vein endothelial cells (HUVECs) to measure in vitro migration with fibronectin-coated Boyden chambers, invasion with Matrigel-coated Boyden chambers, proliferation with a tetrazolium salt, and differentiation with an in vitro Matrigel assay. We investigated new blood vessel formation in vivo by use of Matrigel-filled silicone cylinders implanted under the skin of nude mice and by use of a breast cancer xenograft model with CR-1-transfected or control Neo-transfected MCF-7 human breast cancer cells. We also used a blocking anti-CR-1 monoclonal antibody to investigate the role of CR-1 in angiogenesis in vivo and in vitro. All statistical tests were two-sided. Results: CR-1 stimulated HUVEC proliferation, migration, and invasion and induced HUVEC differentiation into vascular-like structures on Matrigel. In vivo recombinant CR-1 protein induced microvessel formation in Matrigel-filled silicone cylinders, and microvessel formation was statistically significantly inhibited with a blocking anti-CR-1 monoclonal antibody (CR-1 and antibody = 127% of microvessel formation compared with that in untreated control cylinders and CR-1 alone = 259%; difference = 132%, 95% confidence interval [CI] = 123% to 140%; P < .001). Tumors formed by CR-1-transfected MCF-7 cells in the cleared mammary fat pad of nude mice had higher microvessel density than tumors formed by control Neo-transfected MCF-7 cells (CR-1-transfected cells = 4.66 vessels per field and Neo-transfected cells = 2.33 vessels per field; difference = 2.33 vessels per field, 95% CI = 1.2 to 2.8; P = .004). Conclusion: CR-1 appears to have an important role in the multistep process of angiogenesis.
引用
收藏
页码:132 / 141
页数:10
相关论文
共 35 条
  • [11] Distler JHW, 2003, Q J NUCL MED, V47, P149
  • [12] Ebert AD, 1999, CANCER RES, V59, P4502
  • [13] Cripto-1-induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells
    Ebert, AD
    Wechselberger, C
    Nees, M
    Clair, T
    Schaller, G
    Martinez-Lacaci, I
    Wallace-Jones, B
    Bianco, C
    Weitzel, HK
    Salomon, DS
    [J]. EXPERIMENTAL CELL RESEARCH, 2000, 257 (01) : 223 - 229
  • [14] Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase Akt signal transduction pathway -: Requirement for Flk-1/KDR activation
    Gerber, HP
    McMurtrey, A
    Kowalski, J
    Yan, MH
    Keyt, BA
    Dixit, V
    Ferrara, N
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (46) : 30336 - 30343
  • [15] Cripto forms a complex with activin and type II activin receptors and can block activin signaling
    Gray, PC
    Harrison, CA
    Vale, W
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (09) : 5193 - 5198
  • [16] Quantitative assessment of angiogenic responses by the directed in vivo angiogenesis assay
    Guedez, L
    Rivera, AM
    Salloum, R
    Miller, ML
    Diegmueller, JJ
    Bungay, PM
    Stetler-Stevenson, WG
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (05) : 1431 - 1439
  • [17] Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto
    Harms, PW
    Chang, CB
    [J]. GENES & DEVELOPMENT, 2003, 17 (21) : 2624 - 2629
  • [18] SB-431542 is a potent and specific inhibitor of transforming growth factor-β superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7
    Inman, GJ
    Nicolás, FJ
    Callahan, JF
    Harling, JD
    Gaster, LM
    Reith, AD
    Laping, NJ
    Hill, CS
    [J]. MOLECULAR PHARMACOLOGY, 2002, 62 (01) : 65 - 74
  • [19] Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells
    Kannan, S
    DeSantis, M
    Lohmeyer, M
    Riese, DJ
    Smith, GH
    Hynes, N
    Seno, M
    Brandt, R
    Bianco, C
    Persico, G
    Kenney, N
    Normanno, N
    MartinezLacaci, I
    Ciardiello, F
    Stern, DF
    Gullick, WJ
    Salomon, DS
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (06) : 3330 - 3335
  • [20] Differential mitogenic responses of human macrovascular and microvascular endothelial cells to cytokines underline their phenotypic heterogeneity
    Lang, I
    Hoffmann, C
    Olip, H
    Pabst, MA
    Hahn, T
    Dohr, G
    Desoye, G
    [J]. CELL PROLIFERATION, 2001, 34 (03) : 143 - 155